         |
|
|
|
|
|
|
|||
Conor
Announces Two-Year Results from EuroSTAR Trial of the CoStar Drug-Eluting Stent |
|||
| September 5, 2006 -- After 24 months, the Conor CoStar stent seems to be fulfilling its promise as a new generation drug-eluting stent that may eliminate several of the problems, such as late stent thrombosis and long-term antiplatelet therapy, that have been hotly discussed over the past few days at the World Congress of Cardiology in Barcelona. In the words of Dr. Keith Dawkins of Southampton University Hospital in the UK, "There were low rates of clinical events through 24 months, demonstrating the stability of outcomes with the CoStar stent.... With its low profile and high radiopacity, the CoStar stent is highly deliverable. In addition, the use of bioresorbable polymers ensures that no permanent polymer residue or drug remains at the target site, which may confer a long-term advantage with respect to reduced rates of late stent thrombosis." At 24-months, the target lesion revascularization rate was 3.6 percent, up slightly from 2.8 percent at the one-year mark. This data shows the CoStar to be in the same class of restenosis prevention as the Taxus and Cypher. The MACE, or major adverse cardiac event, rate was 10.4 percent. Of great interest is that there were no reported cases of stent thrombosis with the CoStar between the cessation of anti-platelet therapy at six months and 24-month follow-up. This is different from what was seen in Sunday's presentation of meta-analyses, showing continued long term stent thrombosis in the Taxus and Cypher stents, and bolsters Conor's claim that its polymer is reabsorbed within this initial period, converting the CoStar into a bare metal stent for the long term. related
stories:
|
|||
Angioplasty.Org Home • PatientCenter send comments & suggestions
to "info at angioplasty dot org" |
|||